A new polycythemia vera (PV) drug developed by PharmaEssentia Corp (PEC, 藥華醫藥) is likely to be a major growth catalyst next year, after it obtains approval for commercialization in the US and European markets, analysts said.
The new drug, P1101, is a long-acting interferon that should produce positive results in phase-three clinical trials, Yuanta Securities Investment Consulting Co (元大投顧) analyst Peggy Lee (李珮菁) said in a note on Tuesday.
“Its launch in the US and EU markets should usher in rapid sales growth,” Lee said, forecasting PharmaEssentia sales to grow from this year’s NT$17 million (US$524,837) to NT$1.38 billion next year and to NT$3.23 billion in 2018.
The company is also expected to improve its balance sheet by posting a net profit of NT$163 million next year from a net loss of NT$877 million this year, with profit surging to NT$1.2 billion in 2018, Lee said.
Interferons are signaling proteins made and released by host cells in response to the presence of viruses, bacteria, parasites and tumor cells that cause cells to heighten their anti-viral defenses.
PharmaEssentia said its pegylation technology platform is designed to increase the efficacy of protein drugs by prolonging their circulation in the bloodstream by targeting polyethylene glycol at a specific and defined region of the protein.
Daiwa Capital Markets analyst Christine Wang (王琦清) said P1101 has been designated an orphan drug by European and US authorities, which grants a number of incentives, such as periods of exclusive sales rights.
Orphan drug status would bring fast-track status and pricing benefits for the company, Wang said in a note earlier this month.
Taipei-based PharmaEssentia — which is set to shift its shares to the over-the-counter Taipei Exchange from the prepartory Emerging Stock Market on July 19 — has licensed Austria-based AOP Orphan Pharmaceuticals AG for the sales of P1101 in Europe.
The company is seeking a partner to oversee the drug’s commercialization in the US and has plans to gain approval for P1101 as a treatment for essential thrombocythemia, hepatitis B and C, Wang said.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
MAJOR BENEFICIARY: The company benefits from TSMC’s advanced packaging scarcity, given robust demand for Nvidia AI chips, analysts said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it is raising its equipment capital expenditure budget by 10 percent this year to expand leading-edge and advanced packing and testing capacity amid strong artificial intelligence (AI) and high-performance computing chip demand. This is on top of the 40 to 50 percent annual increase in its capital spending budget to more than the US$1.7 billion to announced in February. About half of the equipment capital expenditure would be spent on leading-edge and advanced packaging and testing technology, the company said. ASE is considered by analysts